Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28

Impact · against what's priced in

Viking Therapeutics faces a pivotal catalyst on October 28, where specific Phase 3 SUNRISE trial parameters will determine commercial timelines. While maintenance data and recent capital raises provide a floor, the stock's recent 41% decline reflects deep skepticism regarding R&D burn and competitive positioning against incumbents.

VKTX+0.20: No priced-in read yet

Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28

What matters in this story

Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts

Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28

What matters in this story

Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts

How each ticker is affected

Connected tickers

Track these names every morning.

Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck's Q3 Results on Oct. 29

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026

Invisalign's Moment of Truth: Will International Growth Save ALGN on Oct 28?

Wall Street Brunch: Fed And Hyperscaler Earnings

Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28

What matters in this story

Next reads from the same story arc

Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts

Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28

What matters in this story

Next reads from the same story arc

Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts

How each ticker is affected

Connected tickers

Track these names every morning.

Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck's Q3 Results on Oct. 29

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026

Invisalign's Moment of Truth: Will International Growth Save ALGN on Oct 28?

Wall Street Brunch: Fed And Hyperscaler Earnings